# T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer

> **NCT02073916** · PHASE1 · COMPLETED · sponsor: **Jenny C. Chang, MD** · enrollment: 24 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** T-DM1
- **DRUG:** Lapatinib
- **DRUG:** Abraxane

## Key facts

- **NCT ID:** NCT02073916
- **Lead sponsor:** Jenny C. Chang, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02073916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02073916, "T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02073916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*